Prapotnich Dominique, Sánchez-Salas Rafael, Cathelineau Xavier, Stakhovskyi Oleksandr, Rocha José E A, Vallancien Guy
Urology Department, Institut Mutualiste Montsouris, Université Paris Descartes, Paris, France.
Arch Esp Urol. 2009 Nov;62(9):689-94. doi: 10.4321/s0004-06142009000900001.
To review the literature and present a contemporary image of androgen deprivation for prostate cancer.
We conducted a PubMed search on intermittent androgen deprivation. Articles obtained on intermittent androgen deprivation (IAD) and the experiences at Institut Montsouris were used for the review.
IAD is an approach to hormonal deprivation that holds effective cancer control while preventing the morbidity associated with continuous androgen blockade. IAD nuances have been assessed by urological community teams in order to verify its possible potential benefits. Evidence based approach supports the idea of IAD as a standard of therapy for advanced prostate cancer requiring hormone deprivation. Variation among medical teams' criteria for the treatment and surveillance await standardization.
Reassessing the gold standard of hormonal blockade in advanced prostate cancer is mandatory.The undeniable evolution of IAD needs to be embraced by the urological community.
